Viral load blips above 50 copies/ml are associated with an increased risk of subsequent treatment failure and need to be taken seriously as signals of non-adherence and emerging drug resistance, investigators from the EuResist study report in the journal Clinical Infectious Diseases.
But the study also found that the vast majority of people who experienced a viral blip or low-level viraemia went on re-suppress HIV and did not experience virologic failure.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.